Company

Brii Biosciences Launches BRiSC Bispecific siRNA Platform – Dual‑Target RNAi Engine to Advance Next‑Generation RNA Therapeutics in Prevalent Diseases
Brii BiosciencesHKG: 2137

Brii Biosciences Launches BRiSC Bispecific siRNA Platform – Dual‑Target RNAi Engine to Advance Next‑Generation RNA Therapeutics in Prevalent Diseases

Brii Biosciences Limited (HKG: 2137) announced the launch of its proprietary BRiSC (Bispecific RNAi iSilenCing) small interfering RNA (siRNA) drug discovery platform, designed to advance the development of next‑generation ribonucleic…

AbbVie's RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance

AbbVie’s RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance

CSPC Pharmaceutical's Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval – PD‑1/VEGFA/CTLA‑4 Candidate Targets Advanced and Metastatic Solid Tumors

CSPC Pharmaceutical’s Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval – PD‑1/VEGFA/CTLA‑4 Candidate Targets Advanced and Metastatic Solid Tumors

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
DaShenLin PharmaceuticalHKG: 0314

Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses

Clinical trial approval / initiationKangtai Biological Products

Kangtai Biological Initiates Phase I Clinical Study for Trivalent Influenza Split Vaccine Produced in MDCK Cells

AbbVieNYSE: ABBV

AbbVie Announces $1.4 Billion Advanced Manufacturing Campus in North Carolina to Support Immunology, Neuroscience, and Oncology Portfolio

AIGoogle

Merck & Co. Announces $1 Billion Strategic Partnership with Google Cloud to Deploy Enterprise-Wide Agentic AI Platform

Show More